Advertisement
Home 2019

Archives

Dupilumab is associated with significantly reduced severe exacerbation rates in patients with late-onset asthma with or without fixed airway obstruction

Dupilumab Cuts Exacerbations in Late-Onset Asthma

0
Lung function improved at weeks 12 and 52 in patients with, without fixed airway obstruction
Four distinct clinical phenotypes have been identified among patients with sepsis

Four Clinical Phenotypes Identified for Sepsis

0
Phenotype distributions similar in derivation, validation cohorts; highest mortality for γ phenotype
Ingestion of a button battery can cause mucosal damage in pediatric patients

DDW: Ingested Button Battery Can Cause Gastric Injury

0
Eighty-six percent of pediatric patients with BB ingestion had visual evidence of mucosal damage
For patients with moderate-to-severe acute respiratory distress syndrome receiving mechanical ventilation

Early Neuromuscular Blockade No Better in ARDS Patients on Vent

0
Mortality similar for those receiving continuous infusion of cisatracurium, lighter sedation targets
For patients with mild asthma with a low sputum eosinophil level

Mometasone, Tiotropium Do Not Top Placebo in Mild Asthma

0
And budesonide-formoterol superior to albuterol for prevention of asthma exacerbations
Adolescents and adults who undergo gastric bypass surgery have similar weight loss at five years after surgery

Magnitude of Weight Loss Similar for Teens, Adults After RYGB

0
Adolescents significantly more likely to have remission of type 2 diabetes and hypertension
A low-fat dietary intervention is associated with reductions in deaths after breast cancer and deaths from breast cancer among postmenopausal women after long-term follow-up

ASCO: Low-Fat Dietary Pattern Cuts Breast Cancer Deaths

0
Significant reduction in deaths from breast cancer after cumulative follow-up of 19.6 years
From 2004 to 2012

Herpes Zoster Ophthalmicus Cases Increased in 2004 to 2012

0
Highest rates of HZO seen in older adults, women, and in whites versus other racial groups
The selective Bruton's tyrosine kinase inhibitor evobrutinib at a dose of 75 mg once daily is associated with fewer enhancing lesions during weeks 12 through 24 among patients with relapsing multiple sclerosis

AAN: Oral BTK Inhibitor Superior to Placebo in Multiple Sclerosis

0
Fewer enhancing lesions seen in weeks 12 to 24 for 75 mg evobrutinib once daily versus placebo
Use of an electrical current to measure extracellular fluid volume -- bioimpedance spectroscopy -- may identify postoperative breast cancer patients at risk for lymphedema at an earlier stage

Bioimpedance Spectroscopy May Identify Lymphedema Earlier

0
Surveillance with the technology may allow earlier detection, more effective treatment for lymphedema